![Myeloma Paper of the Day, August 23rd, suggested by Robert Orlowski](https://oncodaily.com/pub/uploads/2024/08/Myeloma-Paper-of-the-Day-1.jpg)
Myeloma Paper of the Day, August 23rd, suggested by Robert Orlowski
Robert Z. Orlowski shared a post on X:
“Myeloma Paper of the Day: Study of teclistamab efficacy and safety in relapsed/refractory myeloma post-BCMA-targeting txs shows good ORR of 52.5% and median PFS 4.5 months with neutropenia, infections, cytokine release syndrome and anemia as main AEs.”
Authors: Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, and Alfred Garfall.
Source: Robert Z. Orlowski/X
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.